Organization · Accelerator
Accelerator Life Science Partners
Accelerator Life Science Partners is a venture capital firm based in New York City that focuses on building early-stage biotechnology companies. They provide a comprehensive toolkit of business, scientific, and financial resources to support the commercialization of innovative biotech solutions.
Overview
What Accelerator Life Science Partners does
What Accelerator Life Science Partners is
Accelerator Life Science Partners is a venture capital firm based in New York City that focuses on building early-stage biotechnology companies. They provide a comprehensive toolkit of business, scientific, and financial resources to support the commercialization of innovative biotech solutions.
How it participates in the startup ecosystem
The current public profile supports funder and program host capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Accelerator
- Structured capabilities
- Funder · Program host
- Last reviewed
- March 5, 2026
What Accelerator means
An accelerator is a structured, short-term program designed to speed up a startup's progress toward product-market fit, traction, fundraising, or scale.
Open the glossary entryOfficial channels
Find Accelerator Life Science Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Accelerator Life Science Partners as a funder
Investment thesis
Accelerator Life Science Partners invests in early-stage biotechnology companies, emphasizing the development and commercialization of breakthrough innovations that can impact global health.
Focus narrative
Accelerator Life Science Partners focuses on investing in early-stage biotechnology companies. They provide a comprehensive toolkit that includes business, scientific, and financial resources to enhance the success of their portfolio companies. Their investment strategy prioritizes the development and commercialization of breakthrough biotechnology innovations that have the potential to significantly impact global health.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Regions
- AsiaNorth America
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 5
- Recorded notable exits
- Rodeo Therapeutics
Portfolio context
Notable portfolio companies include: Rodeo Therapeutics (developing an oral inhibitor for inflammatory bowel disease, acquired by Amgen for up to $721 million), ApoGen (addressing drug resistance in cancer therapy), Lodo Therapeutics (collaboration with Genentech potentially worth up to $969 million), Petra Pharma (acquired after a $48 million Series A financing), and Proniras (developing a compound for nerve agent-induced seizures).
Capability profile
Accelerator Life Science Partners as a program host
Program thesis
Accelerator Life Science Partners aims to address the challenges of starting new businesses in the biotech sector by offering a comprehensive toolkit of business, scientific, and financial resources.
Focus narrative
The program focuses on early-stage biotechnology companies, emphasizing the development and commercialization of breakthrough innovations that can significantly impact global health. Accelerator provides a comprehensive toolkit that includes business, scientific, and financial resources tailored to the unique needs of biotech startups.
Value and support
Founders participating in the program receive access to critical resources, mentorship from industry experts, and financial support to accelerate their company's growth. Accelerator's extensive network and expertise in the biotech sector provide invaluable guidance throughout the startup journey.
Availability
- Application state
- Not published
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Sectors
- Biotech & Life Sciences
- Regions
- AsiaNorth America
Alumni and track record
Alumni context
Notable alumni include Rodeo Therapeutics, acquired by Amgen for up to $721 million; ApoGen, which focuses on drug resistance in cancer therapy; and Lodo Therapeutics, which achieved a collaboration with Genentech potentially worth up to $969 million.
Common questions
What to know about Accelerator Life Science Partners
Upseed classifies Accelerator Life Science Partners under the Accelerator organization type. Its current public profile includes funder and program host capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.